Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
McKinsey
Fish and Richardson
Mallinckrodt
Citi
Covington
Medtronic
Julphar
Dow
Express Scripts

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,835,455

« Back to Dashboard

Which drugs does patent 8,835,455 protect, and when does it expire?

Patent 8,835,455 protects AVYCAZ and is included in one NDA.

This patent has seventeen patent family members in eleven countries.
Summary for Patent: 8,835,455
Title:Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Abstract: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.
Inventor(s): Dedhiya; Mahendra G. (Pomona, NY), Bhattacharya; Sisir (Hauppauge, NY), Ducandas; Veronique (Vitry sur Seine, FR), Giuliani; Alexandre (Villecresnes, FR), Ravaux; Valerie (Reyrieux, FR), Bonnet; Alain (Chateau-Thierry, FR), Priour; Alain (Paris, FR), Spargo; Peter (Deal, GB)
Assignee:
Application Number:13/901,724
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,835,455

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cerexa AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,835,455

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France09 04864Oct 9, 2009

Non-Orange Book US Patents Family Members for Patent 8,835,455

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,471,025 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Subscribe
9,062,053 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Subscribe
9,580,424 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,835,455

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2012118247 ➤ Subscribe
Mexico 2012003730 ➤ Subscribe
South Korea 20120106720 ➤ Subscribe
Japan 2017149754 ➤ Subscribe
Japan 6197170 ➤ Subscribe
Japan 2016029082 ➤ Subscribe
Japan 6072540 ➤ Subscribe
Japan 2013507346 ➤ Subscribe
Israel 239663 ➤ Subscribe
Israel 218565 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Cantor Fitzgerald
Chubb
Boehringer Ingelheim
McKinsey
Queensland Health
Deloitte
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot